176 related articles for article (PubMed ID: 28225038)
1. Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis.
Procaccia S; Ordan M; Cohen I; Bendetz-Nezer S; Seger R
Sci Rep; 2017 Feb; 7():43078. PubMed ID: 28225038
[TBL] [Abstract][Full Text] [Related]
2. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
[TBL] [Abstract][Full Text] [Related]
3. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
4. MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.
Kocieniewski P; Lipniacki T
Phys Biol; 2013 Jun; 10(3):035006. PubMed ID: 23735655
[TBL] [Abstract][Full Text] [Related]
5. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.
Burgermeister E; Chuderland D; Hanoch T; Meyer M; Liscovitch M; Seger R
Mol Cell Biol; 2007 Feb; 27(3):803-17. PubMed ID: 17101779
[TBL] [Abstract][Full Text] [Related]
6. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
10. MEK1 activation by PAK: a novel mechanism.
Park ER; Eblen ST; Catling AD
Cell Signal; 2007 Jul; 19(7):1488-96. PubMed ID: 17314031
[TBL] [Abstract][Full Text] [Related]
11. MEK1/2 dual-specificity protein kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953
[TBL] [Abstract][Full Text] [Related]
12. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
Roy M; Li Z; Sacks DB
Mol Cell Biol; 2005 Sep; 25(18):7940-52. PubMed ID: 16135787
[TBL] [Abstract][Full Text] [Related]
13. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
15. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
Wu PK; Hong SK; Park JI
Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
[TBL] [Abstract][Full Text] [Related]
16. Glutathione transferase Omega 1-1 (GSTO1-1) modulates Akt and MEK1/2 signaling in human neuroblastoma cell SH-SY5Y.
Saisawang C; Wongsantichon J; Robinson RC; Ketterman AJ
Proteins; 2019 Jul; 87(7):588-595. PubMed ID: 30874320
[TBL] [Abstract][Full Text] [Related]
17. A novel MEK2/PI3Kδ pathway controls the expression of IL-1 receptor antagonist in IFN-β-activated human monocytes.
Brandt KJ; Carpintero R; Gruaz L; Molnarfi N; Burger D
J Leukoc Biol; 2010 Dec; 88(6):1191-200. PubMed ID: 20837746
[TBL] [Abstract][Full Text] [Related]
18. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
19. MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.
Liu SY; Liang Y; Lin TX; Su F; Liang WW; Uwe H; Li Y
Chin Med J (Engl); 2012 Dec; 125(23):4197-201. PubMed ID: 23217386
[TBL] [Abstract][Full Text] [Related]
20. Intrinsically active MEK variants are differentially regulated by proteinases and phosphatases.
Ordan M; Pallara C; Maik-Rachline G; Hanoch T; Gervasio FL; Glaser F; Fernandez-Recio J; Seger R
Sci Rep; 2018 Aug; 8(1):11830. PubMed ID: 30087384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
